CG Oncology Inc. on Wednesday filed for an initial public offering to trade on the Nasdaq under the symbol “CGON” with underwriters Morgan Stanley, Goldman Sachs, Cantor and LifeSci Capital. The Irvine, Calif.-based company is a late-stage biopharmaceutical company that’s developing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Its product candidate, cretostimogene, is initially in clinical development for the treatment of patients with high-risk non-muscle-invasive bladder cancer. Principal shareholders of the company include ORI Capital entities, Decheng Capital Global Life Sciences Fund IV and entities affiliated with Longitude Venture Partners.
Read the full article here